TASLY(SH:600535) Ge Long Hui A P P·2025-09-23 08:46Core Viewpoint - The report from Open Source Securities highlights that Tianshili has announced a new indication for its proprietary biological innovative drug, Recombinant Human Urokinase (Puyouke), for thrombolytic treatment of acute ischemic stroke, marking its second approved indication in China [1] Group 1: Product Development - Puyouke was approved as a Class 1 biological innovative drug during the "11th Five-Year Plan" under the national "Major New Drug Creation" technology major project, initially for acute ST-segment elevation myocardial infarction [1] - The new indication for acute ischemic stroke is expected to enhance the drug's market potential and reflects the company's strategic focus on expanding its product offerings [1] Group 2: Financial Projections - The company maintains its profit forecasts for the years 2025 to 2027, estimating net profits of 1.183 billion, 1.306 billion, and 1.455 billion yuan respectively [1] - Earnings per share (EPS) are projected to be 0.79, 0.87, and 0.97 yuan per share for the same years, with corresponding price-to-earnings (PE) ratios of 19.8, 18.0, and 16.1 times [1] Group 3: Investment Rating - The report maintains a "Buy" rating for the stock, indicating confidence in the company's growth potential driven by the dual indications of Puyouke [1]